O’Neal and colleagues developed and evaluated SLAMF7 CAR T cells targeting the V domain of SLAMF7 (Luc90-SLAMF7 CAR T) and demonstrated anti-myeloma killing in vitro and in vivo using two myeloma mouse models (180). This evidence concerns the gene SLAMF7 and plasma cell myeloma.